ReviewClinical ophthalmology (Auckland, N.Z.)2016
Genetics and age-related macular degeneration: a practical review for the clinician.
Review in Clinical ophthalmology (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Trends, hotspots, and future directions of inflammation in age-related macular degeneration: A 20-year bibliometric study.Medicine · 2026Article
- Development of self-healing hydrogels to support choroidal endothelial cell transplantation for the treatment of early age related macular degeneration.Acta biomaterialia · 2025Article
- Review
- Current Views on Chr10q26 Contribution to Age-Related Macular Degeneration.Advances in experimental medicine and biology · 2023Review
- Article
- Polymorphism rs11200638 enhanced HtrA1 responsiveness and expression are associated with age-related macular degeneration.Eye (London, England) · 2022Article
- Associations of Tumor Necrosis Factor-Alpha Gene PolymorphismsLife (Basel, Switzerland) · 2022Article
- Evaluation ofExperimental biology and medicine (Maywood, N.J.) · 2021Article
- Associations ofClinical ophthalmology (Auckland, N.Z.) · 2021Article
- Genetics and genetic testing for age-related macular degeneration.Eye (London, England) · 2018Review
- Views of ophthalmologists on the genetics of age-related macular degeneration: Results of a qualitative study.PloS one · 2018Article
- DNA Methylomes Reveal Biological Networks Involved in Human Eye Development, Functions and Associated Disorders.Scientific reports · 2017Article
- Protective Effect of Met12, a Small Peptide Inhibitor of Fas, on the Retinal Pigment Epithelium and Photoreceptor After Sodium Iodate Injury.Investigative ophthalmology & visual science · 2017Article
- Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors.Eye and vision (London, England) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Age-related macular degeneration is a complex disease, with both genetic and environmental risk factors interacting in unknown ways. Currently, 52 gene variants within 34 loci have been significantly associated with age-related macular degeneration. Two well-studied major genes are complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2). There exist several commercially available tests that are proposed to stratify patients into high-risk and low-risk groups, as well as predict response to nutritional supplementation. However, at present, the bulk of the available peer-reviewed evidence suggests that genetic testing is more useful as a research tool than for clinical management of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.